FIG. 1




Assessed for eligibility (n=38)
Excluded (n=8):
• 4 patients withdrew consent
• 1 was excluded secondary to malignancy
• 3 did not meet the inclusion criteria
Randomized and Infused (n=30)
Allogeneic hMSCs – 100 million cells
• n=10 administered study product
o No infusions stopped
o No persistent cardiorespiratory signs/symptoms following infusion
Allogeneic hMSCs – 200 million cells
• n=10 administered study product
o No infusions stopped
o No persistent cardiorespiratory signs/symptoms following infusion
Placebo
• n=10 administered study product
o No infusions stopped
o No persistent cardiorespiratory signs/symptoms following infusion
10 completed one year follow-up
• 0 withdrawn
• 0 lost to follow-up
• 0 died
• 0 pulmonary embolisms
• 0 strokes
9 completed one year follow-up
• 0 withdrawn
• 0 lost to follow-up
• 1 died of congestive heart failure 327 days post-infusion
• 0 pulmonary embolisms
• 0 strokes
10 completed one year follow-up
• 0 withdrawn
• 0 lost to follow-up
• 0 died
• 0 pulmonary embolisms
• 1 experienced a stroke 307 days post-infusion

FIG. 2


Sexual Quality of Life Questionnaire
35
30
25
20
15
10
5
0
-5
-10
-15
-20
*
*
*
Day 30
Day 90
Day 180
20-M N=5
100-M N=5
200-M N=5